Travere Therapeutics Ownership
| TVTX Stock | USD 22.91 0.81 3.41% |
Shares in Circulation | First Issued 2011-12-31 | Previous Quarter 78 M | Current Value 78 M | Avarage Shares Outstanding 41.5 M | Quarterly Volatility 21.4 M |
Travere |
Travere Stock Ownership Analysis
About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 4.52. Travere Therapeutics had not issued any dividends in recent years. The entity had 1:9 split on the 8th of November 2011. Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Travere Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 310 people. To find out more about Travere Therapeutics contact Eric Dube at 888 969 7879 or learn more at https://www.travere.com.Besides selling stocks to institutional investors, Travere Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Travere Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Travere Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Travere Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Travere Therapeutics Insider Trades History
Less than 1% of Travere Therapeutics are currently held by insiders. Unlike Travere Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Travere Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Travere Therapeutics' insider trades
Travere Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Travere Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Travere Therapeutics backward and forwards among themselves. Travere Therapeutics' institutional investor refers to the entity that pools money to purchase Travere Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Finepoint Capital Lp | 2024-09-30 | 1.8 M | Geode Capital Management, Llc | 2024-09-30 | 1.7 M | Bank Of America Corp | 2024-09-30 | 1.7 M | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 1.6 M | Jpmorgan Chase & Co | 2024-09-30 | 1.5 M | Kynam Capital Management, Lp | 2024-09-30 | 1.4 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.3 M | Balyasny Asset Management Llc | 2024-09-30 | 1.3 M | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 1.2 M | Armistice Capital, Llc | 2024-09-30 | 7.6 M | Blackrock Inc | 2024-09-30 | 7.6 M |
Travere Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Travere Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Travere Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Travere Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Travere Therapeutics Outstanding Bonds
Travere Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Travere Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Travere bonds can be classified according to their maturity, which is the date when Travere Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| TRAVELERS PPTY CAS Corp BondUS89420GAE98 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Travere Therapeutics Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 12th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 11th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.